卡巴马泽平和莱维他对凝血参数的影响: 血栓凝血时间,活性部分血栓形成时间,D- 模和纤维素水平
Jiaohui Li1, Chengyun Zhong1, Guanji Bian2
1Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Taizhou Branch, Department of Neurology, Taizhou, Zhejiang Province, China.
Journal of medical biochemistry
|August 21, 2025
概括
尽管两者都有效控制部分发作的发作,但卡巴马西平对凝血测试的影响更大. 利维对血液凝固具有较轻的作用.
科学领域:
- 神经学
- 药理学
- 血液学
背景情况:
- 是一种常见的神经疾病,需要有效的治疗策略.
- 评估抗药对凝血的影响对于患者的安全至关重要.
研究的目的:
- 为了比较卡巴马西平和 levetiracetam 单一治疗对凝血参数的影响.
- 用这些药物治疗部分发作的患者的控制.
主要方法:
- 89名患有部分发作的患者被分为卡巴马西平和莱维他组.
- 在6个月内监测了凝血测试 (前血红素时间,aPTT,纤维素素,D- 模体) 和发作频率.
主要成果:
- 与基线相比,卡巴马西平显著降低了PT,aPTT和D- 模度;而 levetiracetam则显示出较少明显的变化.
- 这两组的纤维素都下降了. 所有患者的发作频率都有所降低.
- 在两组治疗中,控制率相似.
结论:
- 卡巴马西平可能会增加凝血异常的风险,但对控制发作有效.
- 利维对凝血具有较轻的作用,并具有类似的治疗效果.
相关概念视频
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
446
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
446
Anticoagulant Drugs: Low-Molecular-Weight Heparins
893
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
893
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Antiepileptic Drugs: Potassium Channel Activators
274
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
274
Antiepileptic Drugs: GABAergic Pathway Potentiators
640
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
640


